Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AC Immune SA    ACIU   CH0329023102

AC IMMUNE SA (ACIU)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
13.2(c) 16.04(c) 14.9(c) 13.77(c) 12.41 Last
113 158 878 110 252 526 112 438 228 142 Volume
+0.61% +21.52% -7.11% -7.58% -9.88% Change
More quotes
Financials (USD)
Sales 2018 5,15 M
EBIT 2018 -57,3 M
Net income 2018 -56,9 M
Finance 2018 62,9 M
Yield 2018 -
Sales 2019 9,44 M
EBIT 2019 -63,5 M
Net income 2019 -57,6 M
Debt 2019 6,28 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 166x
EV / Sales2019 98,2x
Capitalization 920 M
More Financials
Company
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products.It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative... 
More about the company
Surperformance© ratings of AC Immune SA
Trading Rating : - Investor Rating :
More Ratings
Latest news on AC IMMUNE SA
07/06AC Immune Announces Results of Annual General Meeting
GL
05/02AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
GL
04/05AC Immune Announces the Selection of Tau Small Molecules for Clinical Develop..
GL
03/20AC Immune reports full-year 2017 financial results - successful first year as..
GL
03/15AC Immune prepares for a first in human study of a promising positron emissio..
GL
02/06AC Immune to Participate in Two Investor Conferences and Provide Scientific U..
GL
2017AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therape..
GL
2017AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diag..
GL
2017AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into P..
GL
2017AC Immune to Present at Two Investor Conferences and Provide Scientific Updat..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/11Get the latest news and updates for $ASI $LSXMB $VRTV $ACIU $AMN automaticall.. 
07/10AC Immune $ACIU Upgraded at ValuEngine  
07/09DOWNSIDE MOMENTUM ALERT: $ACIU AC IMMUNE SA COMMON ? TradeIdeas via
1
07/07Top Performing Breakout Stocks of the Week
1
07/06Midday Gainers / Losers (07/06/2018)  
More tweets
Qtime:170
News from SeekingAlpha
07/11Midday Gainers / Losers (07/11/2018) 
07/08YOUR DAILY PHARMA SCOOP : Biogen Rallies, AC Immune Goes Up, Not Everyone On Boa.. 
07/06Midday Gainers / Losers (07/06/2018) 
07/06HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (07/06/2018) 
07/06Alzheimer's players in the green on Biogen news 
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | ACIU | CH0329023102 | 4-Traders
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 22,0 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Andrea Pfeifer CEO, Director & Head-Investor Relations
Martin Velasco Chairman
Jörg Hornstein Chief Financial Officer
Andreas Muhs Chief Scientific Officer
Detlev H. Riesner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AC IMMUNE SA7.58%920
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147